Schrödinger, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-08-16
- Employees
- 867
- Market Cap
- -
- Website
- http://www.schrodinger.com
Study of SGR-3515 In Participants With Advanced Solid Tumors.
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Schrödinger, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06463340
- Locations
- 🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1
Recruiting
- Conditions
- High-Risk and Very High-Risk Myelodysplastic SyndromesAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Schrödinger, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05961839
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸TriStar Bone Marrow Transplant, LLC, Nashville, Tennessee, United States
🇺🇸The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1
Recruiting
- Conditions
- MALT LymphomaBurkitt LymphomaPrimary Effusion LymphomaALK-Positive Large B-Cell LymphomaMature B-Cell NeoplasmNon Hodgkin LymphomaDLBCLFollicular LymphomaIRF4 Gene RearrangementEBV-Positive DLBCL, Nos
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Schrödinger, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT05544019
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Napa Research, Pompano Beach, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath